CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Colesevelam HCL +1 moredrug
Likely dose
Colesevelam HCL 625 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00596427
NCT00596427N/ACompleted
CompareCT.gov

Effects of Colesevelam HCl on Hepatic Insulin Sensitivity, Gluconeogenesis, Glucose Absorption and Lipid Synthesis in Subjects With Type 2 Diabetes Mellitus

Carine Beysen·interventional·Posted Jan 17, 2008·Updated Oct 12, 2012

In Brief

A clinical study evaluating Colesevelam HCL and Placebo for Diabetes. Completed, enrolled 60 participants across 3 sites.

Detailed Summary

The mechanism by which colesevelam HCl lowers glucose is not known. Knowledge of the potential mechanism of action is important for defining the role of the drug among oral antidiabetic agents available for use in subjects with diabetes. The objective of this study is to provide insight into the mechanisms of action of colesevelam HCl in T2DM. The mechanisms of interest include hepatic insulin sensitivity, rate of appearance of exogenous glucose and changes in incretin hormone concentrations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 17, 2008
Enrollment StartNov 1, 2007
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.5 years ago

Interventions

Colesevelam HCLdrug

Colesevelam HCL 625 mg: 3 tablets twice per day

Placebodrug

Placebo tablets: 3 tablets twice per day